Nexentis Technologies Inc. Common Stock (NXTS)

FairStock Score: 56/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I begin with the business. Nexentis is a seven-employee micro-cap with two segments: biotechnology work for cancer and inflammatory metabolic diseases, and renewable energy projects. It has no meaningful commercial revenue. In fiscal 2023, the year ended 2023-12-31, revenue was $263,000 and net loss was $6.5 million. In fiscal 2024, the year ended 2024-12-31, revenue was $210,000 and net loss was $5.2 million. In fiscal 2025, the year ended 2025-12-31, revenue was not available and net loss was $4.0 million. In fiscal Q1 2026, the quarter ended 2026-03-31, net loss was $6.6 million. In fiscal Q2 2026, the quarter ended 2026-06-30, net loss was $11.1 million. That is not a business with a durable moat; it is a cash-consuming research effort.

In plain English: Nexentis Technologies is a tiny company that works on cancer and inflammatory disease treatments and also lists renewable energy projects. It has almost no revenue and has lost money in each of the last four years, so the business looks weak and unproven. At $0.70 a share, some simple math says it may look very cheap compared with its assets or past numbers, but those discounts mostly reflect deep losses and losing cash rather than a healthy bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer